This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sun, L.-Q. Articles by Buchegger, F. Search for Related Content PubMed PubMed Citation Articles by Sun, L.-Q. Articles by Buchegger, F.

Timing Effects of Combined Radioimmunotherapy and Radiotherapy on a Human Solid Tumor in Nude Mice¹

Department of Radiation Oncology, University Hospital of Lausanne, 1011 Lausanne [L-Q. S., R-O. M., P. C., F. B.]; Institute of Biochemistry, University of Lausanne, 1066 Epalinges [C-A. V., J-P. M.]; and Division of Nuclear Medicine, University Hospital of Geneva, CH-1211, Geneva 14 [D. O. S., F. B.], Switzerland

Timing effects of radioimmunotherapy (RIT) combined with externalbeam radiotherapy (RT) were assessed in human colon carcinoma xenografts. Initially, dose effects of fractionated RT and RIT were evaluated separately. Then, 30 Gy RT (10 fractions over 12 days) were combined with three weekly i.v. injections of 200 µCi of ¹³¹I-labeled anti-carcinoembryonic antigen monoclonal antibodies in four different treatment schedules. RIT was given either prior to, concurrently, immediately after, or 2 weeks after RT administration. The longest regrowth delay (RD) of 105 days was observed in mice treated by concurrent administration of RT and RIT, whereas the RDs of RT and RIT alone were 34 and 20 days, respectively. The three sequential combination treatments produced significantly shorter RDs ranging from 62 to 70 days. The tumor response represented by the minimal volume (MV) also showed that concurrent administration of RT and RIT gave the best result, with a mean MV of 4.5% as compared to MVs from 26 to 53% for the three sequential treatments. The results were confirmed in a second experiment, in which a RT of 40 Gy was combined with an identical RIT as above (three injections of 200 µCi of ¹³¹I-labeled monoclonal antibodies). At comparable toxicity levels, the maximum tolerated RT or RIT alone gave shorter RDs and less tumor shrinkage compared to simultaneous RT+RIT. These results may be useful for designing clinical protocols of combined RIT and RT.

¹ L-Q. Sun and C-A. Vogel were supported by the 1991 Robert Wenner award of the Swiss Cancer League and by the Cancer League of Solothurn (Akt 615).

² To whom requests for reprints should be addressed, at Division of Nuclear Medicine, University Hospital of Geneva, CH-1211, Geneva 14, Switzerland.

Received 9/16/96. Accepted 2/ 2/97.

This article has been cited by other articles:

				H. Kobayashi, K. Reijnders, S. English, A. T. Yordanov, D. E. Milenic, A. L. Sowers, D. Citrin, M. C. Krishna, T. A. Waldmann, J. B. Mitchell, et al. Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation Clin. Cancer Res., November 15, 2004; 10(22): 7712 - 7720. [Abstract] [Full Text] [PDF]

				C. R. Divgi, J. A. O'Donoghue, S. Welt, J. O'Neel, R. Finn, R. J. Motzer, A. Jungbluth, E. Hoffman, G. Ritter, S. M. Larson, et al. Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer J. Nucl. Med., August 1, 2004; 45(8): 1412 - 1421. [Abstract] [Full Text] [PDF]

				C. A. Znati, M. Rosenstein, T. D. McKee, E. Brown, D. Turner, W. D. Bloomer, S. Watkins, R. K. Jain, and Y. Boucher Irradiation Reduces Interstitial Fluid Transport and Increases the Collagen Content in Tumors Clin. Cancer Res., November 15, 2003; 9(15): 5508 - 5513. [Abstract] [Full Text] [PDF]

				S. Ruan, J. A. O'Donoghue, S. M. Larson, R. D. Finn, A. Jungbluth, S. Welt, and J. L. Humm Optimizing the Sequence of Combination Therapy with Radiolabeled Antibodies and Fractionated External Beam J. Nucl. Med., November 1, 2000; 41(11): 1905 - 1912. [Abstract] [Full Text] [PDF]

				F. BUCHEGGER, A. ROTH, A. ALLAL, Y. M. DUPERTUIS, D. O. SLOSMAN, A. B. DELALOYE, and J-P. MACH Radioimmunotherapy of Colorectal Cancer Liver Metastases: Combination with Radiotherapy Ann. N.Y. Acad. Sci., June 1, 2000; 910(1): 263 - 270. [Abstract] [Full Text] [PDF]